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reproduction in any medium, provided the original work iType II endometrial carcinomas are a highly aggressive group of tumour subtypes
that are frequently associated with inactivation of the TP53 tumour suppressor
gene. We show that mice with endometrium-specific deletion of Trp53 initially
exhibited histological changes that are identical to known precursor lesions of
type II endometrial carcinomas in humans and later developed carcinomas
representing all type II subtypes. The mTORC1 signalling pathway was frequently
activated in these precursor lesions and tumours, suggesting a genetic coopera-
tion between this pathway and Trp53 deficiency in tumour initiation. Consistent
with this idea, analyses of 521 human endometrial carcinomas identified fre-
quent mTORC1 pathway activation in type I as well as type II endometrial
carcinoma subtypes. mTORC1 pathway activation and p53 expression or
mutation status each independently predicted poor patient survival. We suggest
that molecular alterations in p53 and themTORC1 pathway play different roles in
the initiation of the different endometrial cancer subtypes, but that combined
p53 inactivation and mTORC1 pathway activation are unifying pathogenic
features among histologically diverse subtypes of late stage aggressive endo-
metrial tumours.INTRODUCTION
Carcinomas of the endometrium, the mucosa that lines the
uterus, are the most frequently diagnosed malignancies of the
female genital tract (Jemal et al, 2011). Endometrial carcinomasital Zurich, Zurich,
titute of Technology,
rland
l, University of Basel,
h, Zurich, Switzerland
University of Zurich,
þ41 44 635 6814;
Ltd on behalf of EMBO. This
ercial License, which perm
s properly cited.are classified in a dualistic model based on histological
appearance, clinical behaviour and molecular differences (Di
Cristofano & Ellenson, 2007). Type I tumours are endometrioid
endometrial adenocarcinomas (AdCas), which account for 80%
of endometrial malignancies and are characterized by a
relatively high-survival rate (85% at 5 years), due partly to
their frequent early detection. These tumours frequently exhibit
mutations or alterations in oncogenes and tumour suppressor
genes, including PTEN, PIK3CA, PIK3R1, PIK3R2, LKB1, TSC2
and KRAS, that result in activation of the PI3K-AKT-mTORC1
signalling pathway (Catasus et al, 2009; Cheung et al, 2011;
Konopka et al, 2011; Lu et al, 2008; Oda et al, 2005; Salvesen
et al, 2009; Tashiro et al, 1997; Urick et al, 2011; Velasco et al,
2006). Type I tumours are associated with excessive oestrogen
stimulation, frequently harbour mutations in CTNNB1 and
exhibit microsatellite instability (Di Cristofano & Ellenson,
2007). While roughly half of poorly differentiated, high-grade
type I tumours exhibit TP53 mutations, low-grade tumours
rarely displayTP53mutations, suggesting that loss of function ofis an open access article under
its use, distribution and
EMBO Mol Med (2012) 4, 808–824
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progression of type I disease (Lax et al, 2000).
Type II endometrial tumours develop mainly in elderly
women and comprise three different subtypes; serous AdCas,
clear cell AdCas and undifferentiated carcinomas, each
representing approximately 5–10% of all endometrial carci-
noma cases (Di Cristofano & Ellenson, 2007; Prat et al, 2007).
Despite their relative rarity, these tumours contribute to nearly
half of the total number of endometrial cancer-related deaths
due to their highly invasive and metastatic nature. Carcino-
sarcomas (also known as malignant mixed Mu¨llerian tumours)
represent approximately 1–3% of all endometrial malignancies
and comprise both malignant epithelial and mesenchymal
components. These tumours mostly arise as a result of de-
differentiation of high-grade type I or type II AdCas and follow a
highly aggressive clinical course that has a very poor outcome
(Abeln et al, 1997; Wada et al, 1997).
Type II endometrial carcinomas and carcinosarcomas are
associated with different sets of gene mutations to type I
carcinomas. Mutations in PTEN or KRAS and microsatellite
instability are rare in type II tumours (Catasus et al, 2009; Lax
et al, 2000; Tashiro et al, 1997), but there is strong correlative
evidence that mutations in TP53 are involved at the earliest
stage of tumour development. TP53mutations are found in up to
95% of cases of endometrial serous AdCa (Fadare & Zheng,
2009; Zheng et al, 2011). Endometrial serous AdCas are believed
to arise from precursor lesions termed endometrial glandular
dysplasia (EmGD) that progress to a non-invasive cancer termed
endometrial intraepithelial carcinoma (EIC; Fadare & Zheng,
2009; Zheng et al, 2007, 2004, 2011). Approximately 50–75% of
these lesions display TP53 mutations (Jarboe et al, 2009; Jia
et al, 2008; Liang et al, 2004; Zhang et al, 2009). Clusters of cells
displaying strong p53 immunoreactivity can also be infrequently
observed in some morphologically normal endometrial glands,
suggesting that TP53 mutation represents the earliest step of
serous AdCa formation (Jarboe et al, 2009; Zhang et al, 2009).
TP53 mutations also occur at high frequency in endometrial
clear cell AdCas (An et al, 2004; Fadare et al, 2006; Lax et al,
1998) and in carcinosarcomas (Abeln et al, 1997; Kounelis et al,
1998; Soong et al, 1999; Szukala et al, 1999; Taylor et al, 2006;
Wada et al, 1997). Thus, in contrast to type I tumours, type II
tumours are frequently characterized by early mutations in
TP53.
We present functional genetic evidence showing that p53
suppresses the formation of type II endometrial tumours in mice
and have employed a large cohort of human endometrial
carcinomas to demonstrate molecular similarities between
aggressive type I and type II tumours.RESULTS
Analysis of mice with genitourinary tract-specific
Trp53 deletion
The Ksp1.3-Cre transgene drives Cre expression widely in the
kidney epithelium and in the embryonic precursor structures
that give rise to most of the epithelia of the adult genitourinarywww.embomolmed.org EMBO Mol Med 4, 808–824 system (Frew et al, 2008; Shao et al, 2002). In the uterus, Ksp1.3-
Cre activity results in a mosaic pattern of gene deletion in the
endometrial epithelial cells of the lumen and glands (Frew et al,
2008). We attempted to generate a mouse model of endometrial
type II carcinomas by crossing Trp53fl/fl mice (Jonkers et al,
2001), in which loxP sites are present in intron 1 and intron 10 of
the Trp53 gene, the mouse homologue of human TP53, to mice
expressing the Ksp1.3-Cre transgene. PCR-based assays of
genomic DNA from the kidney, uterus and epididymis of these
Ksp1.3-Cre/þ;Trp53fl/fl mice confirmed the genotype and the
presence of Cre-mediated recombination of the loxP-flanked
Trp53 allele (Fig 1A). Real-time PCR analysis demonstrated
reduction in Trp53 mRNA abundance in these tissues in Cre-
expressing mice (Fig 1B). Cohorts of littermate þ/þ; Trp53fl/fl
(hereafter referred to as WT) and Ksp1.3-Cre/þ;Trp53fl/fl
(hereafter referred to as Trp53D/D) mice were analysed at 9–
10weeks (WT, n¼ 5; Trp53D/D, n¼ 7), 24–35weeks (WT, n¼ 8;
Trp53D/D, n¼ 21), 47–58 weeks (WT, n¼ 5; Trp53D/D, n¼ 10)
and 65–79 weeks (WT, n¼ 22; Trp53D/D, n¼ 33). Trp53D/Dmice
developed normally and at 10 weeks of age displayed no
gross morphological alterations in the kidney (Fig 1D), uterus
(Fig 1H and Supporting Information Fig 1D, G, M and P), ureter,
epididymis, vas deferens or vesicular glands (unpublished
observations). Moreover, both male and female Trp53D/D mice
were normally fecund and fertile.
Trp53D/D mice displayed no pathological alterations in the
kidney, ureter, bladder, vas deferens or vesicular glands up until
at least 79 weeks of age. Regions of the epithelium of the corpus
epididymis of male Trp53D/D mice frequently developed a
vacuolated appearance and displayed substantial nuclear atypia
at around 6 months of age (Fig 1F). To our knowledge, these
lesions are unlike any reported lesions in humans. Consistent
with the very low frequency of tumour formation in the human
epididymis, these lesions did not progress to tumours in any of
the 14 male mice in the oldest cohort and were not further
studied.
While no tumours were observed in female mice in the
cohorts up until approximately 1 year of age, 16 of 19 female
mice in the 65–79 week cohort developed a total of 26
independent endometrial tumours of various histological
appearances (Table 1 and Fig 1I–N)). Individual mice frequently
exhibited multiple independent endometrial tumours of differ-
ent histological appearances (Supporting Information Fig 2).
Human serous AdCas of the uterus typically have complex,
branching papillae with cellular budding and usually broad,
thick fibrovascular cores, but occasionally thin to delicate cores.
The nuclei are usually highly atypical (Silverberg et al, 2003).
Many of the mouse lesions displayed almost identical
morphologies with high-grade nuclei, papillary or micropapil-
lary growth patterns and were regarded as serous AdCas. AdCas
composed mainly of clear or hobnail cells arranged in solid,
tubulo-cystic or papillary patterns were classified as clear cell
AdCas. Twelve tumours arose in the lumen of the uterus and
exhibited papillary morphology with characteristics of either
serous AdCa (Fig 1I) or clear cell AdCa (Fig 1J), or in some
instances a mixture of both. In contrast, 11 tumours that arose
from the glandular component of the endometrium displayed an2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 809
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Figure 1. Type II endometrial tumours formed in
older Ksp1.3-Cre; Trp53fl/fl mice.
A. Upper panels: genotyping PCR of tail DNA to
detect the Ksp1.3-Cre transgene (þ denotes
present and  denotes absent) or the Trp53
floxed (fl) or wild-type (þ) allele. Lower panels:
PCR to detect Cre-mediated recombination at
the Trp53 locus using DNA isolated from kidney,
epididymis and uterus of the same mice used in
the upper panels. The position of the recom-
bined band is shown by D.
B. Real-time quantitative PCR analysis of Trp53
mRNA abundance (normalized to 18S RNA
abundance) in indicated tissues from wild-type
(white bars) or Trp53D/D (black bars) mice.
C-H. Haematoxylin and eosin stain of sections of
kidneys (C and D), epididymis (E and F) and
uterus (G and H) from wild-type or Trp53D/D
mice aged 10 weeks (C, D, G and H) or 6 months
(E and F). (I–N) Examples of tumours that arose
in 14–16-month-old knockout mice. Arrow-
heads in (F) highlight atypical nuclei. All scale
bars represent 50mm.
I-N. Serous AdCa with papillary growth pattern (I),
Clear cell AdCa with papillary growth pattern (J),
Serous AdCa with acinar growth pattern (K),
Clear cell AdCa with acinar growth pattern (L).
Carcinosarcoma displaying mixed clear cell and
(heterologous) chrondrosarcoma components
(M), Undifferentiated carcinoma (N).
810acinar pattern of growth and displayed either serous or clear cell
AdCamorphologies (Fig 1K and L). Three carcinosarcomas with
mixed clear cell AdCa components and either chondrosarcoma
(Fig 1M) or rhabdomyosarcoma components also arose.
Additionally, two undifferentiated carcinomas, containing a
mixture of regions of solid, tubulo-cystic and squamous growth
patterns (Fig 1N) arose. Of these latter five lesions, four had
invaded tissues beyond the uterus and one of these had
metastasized throughout the peritoneal cavity, displaying
nodules of tumour growth on the liver, intestines and peritoneal 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.wall. Carcinosarcomas and mixed carcinomas are believed to
result from the de-differentiation of high-grade type I or type II
carcinomas (Abeln et al, 1997; Wada et al, 1997). Supporting
this idea, two of the three tumours of this type that arose in
Trp53D/Dmice were very large tumours (Table 1 and Supporting
Information Fig 3) that contained regions of either clear cell or
undifferentiated carcinoma. One carcinosarcoma contained a
very large region of ‘pure’ tubulo-cystic clear cell AdCa that
likely represents the initial large lesion from which the
carcinosarcoma component is derived (Supporting InformationEMBO Mol Med 4, 808–824 www.embomolmed.org
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812Fig 3). PCR analysis of genomic DNA isolated from 4 of 4 macro-
dissected tumours displayed Cre-mediated recombination at the
Trp53 locus (unpublished observations), indicating that these
tumours arose from Trp53 knockout cells. Thus, three different
histological subtypes of type II endometrial carcinomas, as well
as carcinosarcomas, arose in Trp53D/D mice at high frequency.
Identification of tumour precursor lesions in Trp53D/D mice
Analysis of the non-tumourous endometrium of tumour-bearing
mice identified a series of putative tumour precursor lesions in
the surface epithelium of the lumen and in the epithelium ofA
B
C
D
E
F
G
H
I
Microinvasive AdCa EIC
Serous AdCa (acinar) Serous AdCa (papillary)
EmGD EmGD
EIC EIC
Normal
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.endometrial glands. In longitudinal histological sections of uteri
from 16 mice that contained 26 macroscopically visible tumours
we identified 169 and 191 independent sites of EmGD in the
epithelium lining the glands (Fig 2B) and the lumen (Fig 2F),
respectively. EmGD represents the earliest morphologically
identifiable serous carcinoma precancerous lesion in humans
(Yi & Zheng, 2008; Zheng et al, 2004). The EmGD lesions in the
lumen and glands of Trp53D/Dmice are histologically identical to
human EmGD and are characterized by enlarged and hyper-
chromatic nuclei, prominent nucleoli, nuclear crowding and
loss of basal nuclear localization. In humans, EIC is believed to
arise from EmGD and appears to be the immediate precursor of
serous AdCa (Ambros et al, 1995; Sherman et al, 1995). Serous
EIC is specifically associated with concurrent serous AdCa of the
endometrium but may also be observed in association with clear
cell AdCa (Ambros et al, 1995; Lax et al, 1998). EIC exhibits
single or multiple layers of malignant cells that have replaced
the endometrial surface epithelium or gland. The human EIC
cells have pleomorphic nuclei and frequent mitotic figures,
resembling the cells of high-grade tumours (Sherman et al,
1995). Endometrial glands and lumen in Trp53D/D mice also
displayed numerous sites of EIC (46 and 54, respectively),
characterized by extensive nuclear atypia, multi-layered cellular
growths and the presence of micropapillary projections (Fig 2C
and G). A novel apparent tumour precursor lesion that we term
‘EIC with papillary structures’ was also evident in the lumen
surface epithelium. This lesion, which was identified at 20
discrete sites in these sections, is characterized by a papillary
growth pattern with a fibrovascular core (Fig 2H). The epithelial
components of some of these papillary EIC lesions exhibited
typical clear cell morphology with tubulocystic growth pattern,
cuboidal cells with clear cytoplasm and ‘hobnail’ cells with
apical nuclei that bulge into the lumen. Other lesions displayed
serous morphology with micropapillary features, large vesicular
nuclei with coarse chromatin and prominent nucleoli. Thus,
these EIC lesions appear to be precursor lesions of clear cell and
serous AdCas with papillary growth patterns. An equivalent
intermediate lesion, that we call ‘microinvasive adenocarci-
noma’, was observed 10 times in the glandular compartment of
the endometrium (Fig 2D). Based on their morphologies and
relative frequencies of occurrence, it appears that these lesions
represent a spectrum of histological changes that occur in the
progression from a normal epithelium to a carcinoma,
consistent with the model proposed for human endometrial
serous AdCa (Zheng et al, 2004). AdCas with a papillary growth
pattern in our model appear to form exclusively from the surfaceFigure 2. Precursor lesions and progression model of tumour formation.
A. Normal endometrial glands and lumenal surface epithelium.
B-E. Examples of lesions illustrating the proposed progression model from
EmGD arising in glands (B), to EIC in the glands (C) to microinvasive AdCa
(D) to serous AdCa with acinar growth pattern (E).
F-I. Examples of lesions illustrating the proposed progression model from
EmGD arising in lumenal surface epithelium (F), to EIC in the lumen (G)
to EIC with papillary growth (H) to serous AdCa with papillary growth
pattern (I). Scale bars in A–H depict 50mm and in E and F depicts
200mm.
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Figure 3. Upregulation of P-S6 and P-4E-BP1 at
transition zones of serous AdCa. (A,D,G, J,M, and P)
Haemotoxylin and eosin stain (H&E), (B, E,H,K,N and
Q) P-S6 IHC stain and (C, F, I, L, O and R) P-4E-BP1
IHC stain.
A-F. Two examples of EIC with papillary growth.
G-I. Low-power image of a serous AdCa and
dysplastic adjacent epithelia.
J-L. Non-dysplastic endometrial surface
epithelium from a region that is continuous
with the upper epithelium but outside of the
fields shown in (G–I).
M-O. Zoom of boxed region 1 from (G) to (I) showing
EmGD.
P-R. Zoom of boxed region 2 from (G) to (I) showing
the transition from EmGD (multi-layered
epithelium below/left of the arrowhead) to
EIC/serous AdCa (epithelium above/right of
the arrowhead). Scale bars in (G–I) represent
200mm, in all other panels 50mm.epithelium of the lumen (Fig 2I), whereas AdCas with an acinar
growth pattern arise from endometrial glands (Fig 2E).
Supporting the progression model, and consistent with
observations in human disease (Zheng et al, 2004), the
endometrial epithelium directly surrounding several papillary
AdCas (Fig 3G shows an example) displayed a continuous
transition from normal epithelium (Fig 3J) to EmGD (Fig 3M) to
EIC (Fig 3P) to a papillary AdCa growth pattern (Fig 3P).
Furthermore, all mice in the 24–29-week-old cohort displayed
some regions of EmGD (Supporting Information Fig 1E, H, Nwww.embomolmed.org EMBO Mol Med 4, 808–824 and Q) and all mice in the 47–58-week-old cohort frequently
displayed widespread regions of EmGD and/or EIC (Supporting
Information Fig 1F, I, O and R) but did not display any
tumours. Thus, as they age, Trp53-deficient mice progressively
display a spectrum of endometrial histological alterations
ranging from low-nuclear grade dysplasia through to invasive
high-grade carcinomas. These mice therefore represent the
first model that accurately reproduces the progression and
hallmark morphological features of human type II endometrial
carcinomas.2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 813
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814Molecular analyses of Trp53 mutant endometrial tumours
Since the Ksp1.3-Cre transgene drives gene deletion during
embryogenesis (Frew et al, 2008; Shao et al, 2002) but tumours
do not arise until approximately 14–16 months of age, Trp53
appears to be largely dispensable for the normal formation and
proliferative homeostasis of the endometrium. It is likely that
additional mutations must occur that cooperate with Trp53
mutation to initiate and drive tumour progression. Since 17–
29% of type II endometrial tumours in humans are character-
ized by amplifications of the ERBB2 gene (Konecny et al, 2009;
Morrison et al, 2006; Nofech-Mozes et al, 2008) we analysed
ErbB2 protein expression and activation status using immuno-
histochemical (IHC) staining of sections of mouse uteri
containing a total of 26 type II tumours. One small glandular
clear cell EIC displayed intense staining for ErbB2 and for
phospho-Tyr1248-ErbB2, demonstrating that the expression of
this oncogenic tyrosine kinase receptor is highly upregulated
and activated (Table 1 and Supporting Information Fig 4).
However, no other tumours showed upregulation of ErbB2
expression or activity, implicating pathways other than ErbB2 as
playing a predominant pathogenic role in these tumours.
To investigate the activation status of other signalling
pathways that may be dysregulated, IHC stainingwas conducted
using antibodies that recognize phosphorylated forms of various
signalling molecules. A positive score was given to a tumour
either if the intensity of staining or the frequency of staining in
the epithelial cells was higher than non-tumourous endome-
trium in the same section (see Supporting Information Fig 5 for
an example) Markers of activation of the AKT-mTORC1
signalling axis, including phospho-Ser473-AKT (P-AKT), phos-
pho-Thr421/Ser424-p70 S6 Kinase (P-S6K), phospho-Ser240/
244-ribosomal S6 protein (P-S6) and phospho-Thr37/46-4E-BP1
(P-4E-BP1) were upregulated in a large percentage of the
tumours (Table 1). 21 of 26 tumours displayed positive staining
for at least one marker of the AKT-mTORC1 signalling pathway
and 9 of these were positive for two or more markers. In
contrast, only 5 of 24 tumours were positive for phospho-
Thr202/Tyr204-ERK1/2 (Table 1), one was positive for
phospho-Ser217/221-MEK1/2 and none for phospho-Thr183/
Tyr185-SAPK/JNK (unpublished observations). Thus, type II
endometrial tumours in Trp53D/D mice frequently display over-
activation of the AKT-mTOR C1 signalling cascade but more
rarely of the MAPK signalling cascades. A particularly striking
correlation between activation of the AKT-mTORC1 signalling
pathway and tumour subtype was observed in the group of
papillary lesions, including serous and clear cell AdCas as well
as larger EIC lesions (Table 1).
We took advantage of this correlation as well as the strong
and specific IHC staining pattern of P-S6 and P-4E-BP1 as
sensitive downstream markers of activation of mTORC1 to
further investigate the sequence of events that leads to the
formation of papillary AdCas. Small clusters of elevated staining
for P-S6 were frequently observed in regions of EmGD lesions in
glands (Supporting Information Fig 6A and B) and in the lumen
(Supporting Information Fig 6C and D) of endometria from
Trp53D/D mice. However, regions of EmGD were also observed
that did not display elevated staining for P-S6 (Supporting 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Information Fig 6E and F). Sites of elevated staining corres-
ponded to 18 and 12%, in the glands and lumen, respectively, of
the total number of identified EmGD lesions in the same
samples, suggesting that mTORC1 pathway activation is not
required for the transition from a normal epithelium to EmGD.
Strikingly however, all papillary EIC lesions, even those
papillary outgrowths that comprised only a few cells (Support-
ing Information Fig 6G and H), were strongly positive for P-S6
(Fig 3B and E) and P-4E-BP1 (Fig 3C and F). Moreover, in three
large papillary tumours where it was possible to identify a
continuous transition in the epithelium from normal to EmGD to
EIC to serous or clear cell AdCa, elevated staining for P-S6
(Fig 3H and Q) and for P-4E-BP1 (Fig 3I and R) was observed
precisely at the transition between EIC and papillary AdCa.
These data demonstrate that mTORC1 pathway activation is not
necessary for the formation of EmGD or EIC, but suggest that
they are associated with, or drive, papillary outgrowth, a
frequent feature of aggressive clear cell and serous endometrial
AdCas.
Activation of the PI3K-AKT-mTORC1 pathway occurs
frequently in all subtypes of human endometrial tumours
We constructed two human endometrial carcinoma tissue
microarrays (TMA; see Supporting Information Table 1), in total
comprising tumour punches from 463 endometrioid AdCas
(type I), 34 serous AdCas (type II), 19 clear cell AdCas (type II),
16 undifferentiated carcinomas (type II) and 16 carcinosarco-
mas. A poor patient outcomewas independently associatedwith
type II carcinomas or carcinosarcomas (Supporting Information
Fig 7A), older age at diagnosis (Supporting Information Fig 7B),
high-grade (see later in Fig 6G) or high-FIGO stage (see later in
Fig 6J), validating the TMAs against known clinical parameters
of these tumour types. We immunohistochemically stained
the TMAs using antibodies against proteins or epitopes that
reveal the activation status of the PI3K and/or mTORC1
signalling pathways (p110a, PTEN, P-AKT, phospho-Ser9-
GSK3b (P-GSK3b), phospho-Ser2448-mTOR (P-mTOR), TSC1,
TSC2, P-S6K and P-4E-BP1), or have been previously proposed
to be differentially expressed between different subtypes of
endometrial carcinoma (PAX8, IMP3 and p16; Mhawech-
Fauceglia et al, 2010; Tong et al, 2010; Yemelyanova et al,
2009) or have been shown to predict a poor prognosis (p53,
ErbB2; Catasus et al, 2009; Konecny et al, 2009; Morrison et al,
2006). Examples of tumour spots displaying different IHC scores
for p53 or displaying negative (0) and strong (3) IHC scores for
the other antibodies are shown in Supporting Information Fig 8.
Consistent with our mouse genetic observations that Trp53
suppresses type II endometrial tumours, tumours displaying
frequent and strong nuclear p53 expression, an indicator of TP53
mutation or aberrant stabilization, occurred more frequently in
serous AdCas, clear cell AdCas, carcinosarcomas and undiffer-
entiated carcinomas than in endometrioid AdCas (Fig 4A). High
levels of p16 expression were more frequent in serous AdCas
and carcinosarcomas than in endometrioid AdCas (Fig 4B). High
levels of ErbB2 expression were more frequent in serous AdCas
and clear cell AdCas than in endometrioid AdCas (Fig 4C). PAX8
and IMP3 expression are more frequently high in serous AdCas,EMBO Mol Med 4, 808–824 www.embomolmed.org
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Figure 4. Identification of molecular discriminants of tumour subtype. TMAs were stained with antibodies against (A) p53, (B) p16, (C) ErbB2, (D) PAX8,
(E) IMP3, (F) p110a, (G) PTEN, (H) P-AKT, (I) P-GSK3b, (J) P-mTOR, (K) TSC1, (L) TSC2 (M) P-S6K (cytoplasmic staining), (N) P-S6K (nuclear staining), (O) P-S6 and
(P) P-4E-BP1. Graphs depict cumulative frequency of staining score for each tumour subtype. Fisher’s exact test was used to compare frequency of expression of
eachmarker in each subtype of endometrial cancer pairwise with endometrioid carcinoma. p< 0.05, p<0.01 or p< 0.001, ns, no significant difference. Endo,
endometrioid adenocarcinoma; Ser, serous adenocarcinoma; CC, clear cell adenocarcinoma; Carc, carcinosarcoma; Undif, undifferentiated carcinoma.clear cell AdCas and carcinosarcomas than in endometrioid
tumours (Fig 4D and E). Thus, subsets of type I and type II
tumours displayed different, as well as overlapping, molecular
profiles.
Consistent with the known frequent mutational activation of
the PI3K-AKT-mTORC1 signalling pathway in type I endome-
trioid AdCas this group of tumours frequently displayed
moderate or strong expression of p110a (Fig 4F), P-AKT
(Fig 4H), P-GSK3b (Fig 4I), P-mTOR (Fig 4J), P-S6K (Fig 4M and
N), P-S6 (Fig 4O) and P-4E-BP1 (Fig 4P), as well as frequent lack
or low level of PTEN staining (Fig 4G). Consistent with the
findings in our mouse model, serous AdCas, clear cell AdCas,
carcinosarcomas and undifferentiated carcinomas also fre-
quently displayed a similar PI3K pathway activation signature.
Indeed, the frequency of type II tumours that displayed high
levels of expression of PI3K pathway activation markers (or lowwww.embomolmed.org EMBO Mol Med 4, 808–824 levels of expression of PTEN) were always either statistically
indistinguishable from the frequency displayed by type I
tumours or in many cases were more frequent. Thus,
dysregulation of the PI3K-AKT-mTORC1 signalling pathway is
a unifying molecular feature of many type I and type II
endometrial tumours.
p53 status strongly predicts patient survival in
endometrial carcinomas
Given the overlapping molecular features between subsets of
type I and type II tumours, we sought to identify pathogenic
factors and diagnostic markers for aggressive cases of
endometrial carcinomas in general, irrespective of histological
subtype. Kaplan–Meier survival curves for each marker are
presented in Fig 5. High levels or frequency of expression of p53
(Fig 5A), p16 (Fig 5B), IMP3 (Fig 5E), p110a (Fig 5F), P-GSK3b2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 815
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Figure 5. Identification of individual molecular predictors of patient outcome in endometrial carcinoma. Kaplan–Meier plots of patient survival over time
after diagnosis when patients were grouped according to IHC staining frequency (% strongly positive cells) for (A) p53 or IHC score for (B) p16, (C) ErbB2, (D) PAX8,
(E) IMP3, (F) p110a, (G) PTEN, (H) P-AKT, (I) P-GSK3b, (J) P-mTOR, (K) TSC1, (L) TSC2, (M) P-S6K (cytoplasmic staining), (N) P-S6K (nuclear staining), (O) P-S6 or
(P) P-4E-BP1. Log Rank (Mantel–Cox) tests were conducted to test for equality in the survival expectation of each group.N-values represent the number of patients
in each group.
816(Fig 5I), P-S6 (Fig 5O) or P-4E-BP1 (Fig 5P) all independently
predicted poor survival, emphasizing the importance of p53 and
the PI3K-mTORC1 pathway in controlling the aggressiveness of
endometrial tumours.
We systematically assessed if multiple combinations of any of
these IHC markers may represent a ‘signature’ that is a superior
predictor of survival. To overcome the frequent problem of
missing values in TMA datasets we developed a novel statistical
approach based on a learning model that is invariant to missing
values and results in an easily interpretable and practically
applicable linear model. This learning model generated a hazard 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.score for each endometrial carcinoma patient based on
combinations of marker stainings. The final model was able
to split the patients into a high-risk group and a low-risk group
based on staining patterns for p110a, P-S6, ErbB2 and p53
(Fig 6A). The difference between these groups was highly
statistically significant and the individual contribution of each
marker to this signature is shown by the coefficient confidence
intervals depicted in Fig 6B. The model was validated by a
10-fold cross-validation strategy (Fig 6C). A multivariate Cox
regression model was then learned to assess the influence of
the risk score, age at diagnosis, histological tumour subtype,EMBO Mol Med 4, 808–824 www.embomolmed.org
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818tumour grade and FIGO stage on the overall survival rate
(Fig 6M). In this model, the risk score was the best predictor of
poor outcome (p¼ 0.000107) with a hazard ratio of 5.93 (95%
confidence interval 2.41–14.61). Hence in cases with increased
risk score, the probability of death was approximately six times
higher than in patients with low-risk scores. Age at diagnosis,
tumour grade and FIGO stage also had a significant effect on
overall survival, albeit with lower hazard ratios than the risk
score (Fig 6M). Detailed analysis of the signaturemodel revealed
that p53 is the dominating predictor and that the risk for an
individual patient can be equally well assessed by using p53
staining status alone as by using the entire signature (Fig 6D).
Thus, these analyses demonstrated that p53 status is by far the
most important factor in predicting survival of patients with
endometrial carcinomas.
Learning models were also separately applied to type I and
type II tumours in order to predict a risk score for each
endometrial carcinoma patient (Supporting Information Fig 9).
The model for type I endometrial tumours was able to split the
patients into a high-risk group and a low-risk group based on
staining patterns for p110a, P-AKT, ErbB2 and p53, with p53
again being the dominating predictor. In contrast, the model
learned for type II tumours revealed that P-S6K was the only
IHC-based marker necessary to predict the outcome of patients.
p53 did not show a significant effect on overall survival in type II
tumours.
We next subdivided the endometrial carcinoma patients into
the categories that are currently used for endometrial carcinoma
diagnosis, namely histological subtype, tumour grade and FIGO
stage and investigated the prognostic power of our risk signature
(p110a, P-S6, ErbB2 and p53) and of p53 IHC staining alone in
each of these groups. In each cohort of patients, either p53
staining alone (Fig 6D–L) or the four-marker signature
(Supporting Information Fig 10) was able to predict poor
patient outcome. Almost half of all type I endometrioid tumours,
which are typically considered to be less aggressive tumours,
displayed some degree of strong nuclear p53 staining and this
strongly predicted a poor outcome for this subset of patients
(Fig 6E). In contrast, p53 staining was not predictive of survival
of patients with type II endometrial carcinomas (Fig 6F), likely
because the vast majority of these tumours contain TP53
mutations and perhaps because some of the non-p53 staining
tumours may have lost p53 function by gene deletion or
truncating mutation, which cannot be detected in our assay.
Importantly, while conventional histopathological analysisFigure 6. p53 is the best predictor of patient survival in endometrial cancers
A. Kaplan–Meier plots of low-risk and high-risk patients using a four-marker ri
p110a, P-S6, ErbB2 and p53.
B. Contribution of each marker to the signature represented by coefficients a
C. Patient stratification based on 10-fold cross-validation of the linear risk sc
D-L. Patient stratification based on the median split of p53 expression frequency
staining in type I tumours (E), p53 staining in type II tumours (F), tumour g
tumours (I), tumour FIGO stage (J), p53 staining in FIGO stage I and II tumours
tests were conducted to test for equality in the survival expectation of eac
M. Multivariate Cox regression analysis of factors possibly influencing overall
events¼ 112, 50 observations deleted due to missing values). Carc., carcino
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.predicts a better clinical outcome for grade 1 tumours in
comparison to grade 2 or 3 tumours (Fig 6G), or for FIGO stage I
and II tumours in comparison to FIGO stage III and IV tumours
(Fig 6J), grouping according to p53 IHC score within these
subgroups was able to further stratify these patients according to
risk of death and predicted a poor survival outcome in the early
grade (Fig 6H) and stage (Fig 6K) tumours, as well as in themore
advanced grade (Fig 6I) and stage (Fig 6L) tumours. In this
study, p53 immunoreactivity therefore represents a highly
sensitive and predictive marker that assists with risk stratifica-
tion of endometrial carcinomas.
To validate that our p53 IHC score indeed reflects the
presence of TP53 mutations we performed deep sequencing
analyses (Supporting Information Table 2) of TP53 exons 5–8, in
which mutations were detected previously with high frequency
(http://www.sanger.ac.uk/genetics/CGP/cosmic). Tumour DNA
was isolated from endometrioid (n¼ 56) or serous (n¼ 7)
endometrial carcinomas that displayed different p53 IHC scores.
An average of 2059 sequencing reads per amplicon provided
insight into the heterogeneity of TP53mutations present in each
individual tumour. The number of independent TP53 gene
mutations that cause coding alterations (Fig 7A) and the
cumulative frequencies at which these mutations were repre-
sented in the DNA population (Fig 7B) were similar in all groups
of tumours, regardless of subtype or p53 IHC score. However,
the frequency of the most abundant (dominant) TP53 mutation
in each tumour correlated excellently with the p53 IHC score
(Spearman’s rho¼ 0.6113, p< 0.0001). Groups of tumours that
displayed an IHC score of over 50% contained dominant TP53
mutations that were present at high frequencies in the tumour
DNA population (Fig 7C). Bioinformatic assessment of the
predicted effect of these mutations on the function of the p53
protein revealed that tumours with a high p53 IHC score more
frequently contain dominant mutations that are predicted to
have a highly detrimental effect on protein function (Fig 7D).
Moreover, there is a statistically significant association between
the predicted severity of the TP53 mutation and the abundance
of the mutation within the DNA population of an individual
tumour (Fig 7E). Finally, the presence of a dominant TP53
mutation at a frequency of greater than 33% predicted a poor
patient outcome (Fig 7F). These findings demonstrate a strong
correlation between the p53 IHC score and presence of TP53
gene mutation and suggest that in both type I and serous
endometrial carcinomas that TP53 gene mutations that inhibit
p53 protein function provide a selective advantage to tumour.
sk-model signature for endometrial carcinoma based on staining patterns for
nd confidence intervals.
ore model.
only (D). Kaplan–Meier survival plots of subgroups of patients based on p53
rade (G), p53 staining in grade 1 tumours (H), p53 staining in grade 2 and 3
(K) and p53 staining in FIGO stage III and IV tumours (L). Log Rank (Mantel–Cox)
h group. N-values represent the number of patients in each group.
survival of patients with endometrial carcinoma (n¼360, number of
sarcoma.
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Figure 7. Deep sequencing of TP53 exons 5–8 in endometrial carcinomas.
A. Total number of different mutations affecting the coding sequence in endometrioid or serous carcinomas grouped according to p53 IHC score. There are no
significant differences between groups.
B. Cumulative frequency of sequencing reads exhibiting one or more mutations. Scores of over 100% indicate that multiple independent mutations occur in the
tumour. There are no significant differences between groups.
C. Frequency at which the dominant mutation is represented in the tumour DNA.
D. Percentage of tumours for which the dominant mutations depicted in C are predicted to have no impact or a low, medium or high-negative functional impact
on the p53 protein.
E. Frequency at which the dominantmutation is represented in an individual tumour, grouped according to predicted functional impact of themutation. In A, B, C
and E, statistically significant differences between groups were calculated using a one-way ANOVA and Bonferroni’s multiple comparison test and depicted as
p< 0.05, p< 0.01 or p< 0.001.
F. Kaplan–Meier survival plots of patients based on the frequency of occurrence of the dominant TP53 mutation.cells, resulting in their enrichment in the tumour population and
generation of a highly aggressive tumour.DISCUSSION
We present an accurate mouse model of type II subtypes of
endometrial carcinomas that will facilitate future molecular and
clinical studies of these highly aggressive cancer subtypes.
Molecular genetic studies have demonstrated that different
subtypes of human type II endometrial carcinomas exhibit
frequent and early inactivation or mutation of the TP53 tumour
suppressor gene. We show that deletion of the Trp53 gene in the
mouse endometrium results in the formation of tumours with
very high penetrance at around 14–16 months of age, providingwww.embomolmed.org EMBO Mol Med 4, 808–824 strong functional genetic evidence that Trp53 functions as a
tumour suppressor gene in type II endometrial carcinomas.
These tumours are not only histologically identical to their
human counterparts, but arise from a series of similar
morphologically identifiable precursor lesions. Lesions that
are identical to the EmGD and EIC lesions that are known to be
precursors of human endometrial serous AdCa are observed in
our mouse model. Thus, this model allows the study of the
sequence of molecular and cell biological alterations that occur
during the development and progression of type II endometrial
tumours.
Trp53 gene deletion under the control of the Ksp1.3-Cre
transgene occurs during embryogenesis and induces gene
deletion widely in the kidney and genitourinary tract, yet
tumours arise only in the endometrium in old mice, suggesting2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 819
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820that additional genetic alterations must accumulate and
cooperate with Trp53 deficiency to initiate cancer. The absence
of tumours in tissues other than the endometrium likely reflects
the very low rate of cellular turnover in these tissues in
comparison to the cyclic nature of cellular proliferation in the
endometrium, which presumably allows mutations to fre-
quently accumulate in the absence of p53 function. Indeed, we
identified activation of components of the PI3K and/or mTORC1
signalling cascade in the majority of the type II endometrial
tumours that arose in Trp53 mutant mice. Taking advantage of
the fact that our mouse model allows analysis of numerous
apparent tumour precursor lesions we identified in some
tumours that activation of the mTORC1 pathway is precisely
associated with the transition from an intraepithelial prolifera-
tion pattern to a papillary growth pattern, suggesting that
secondary genetic alterations that lead to activation of the
mTORC1 pathwaymay act to drive progression of tumours from
EmGD or EIC precursor lesions.
Prompted by these observations, TMA analysis of a large
cohort of endometrial cancers demonstrated that activation of
the PI3K-AKT-mTORC1 signalling pathway occurs not only in
type I carcinomas, which are known to be characterized by
frequent activation of this pathway (Catasus et al, 2009; Cheung
et al, 2011; Konopka et al, 2011; Lu et al, 2008; Oda et al, 2005;
Salvesen et al, 2009; Tashiro et al, 1997; Urick et al, 2011;
Velasco et al, 2006), but also at an equivalent or often higher
frequency in serous AdCas, clear cell AdCas, undifferentiated
carcinomas and carcinosarcomas. Moreover, IHC markers of
activation of this pathway independently predict poor patient
survival, highlighting the importance of this signalling pathway
in endometrial tumour behaviour. Thus, PI3K and/or mTORC1
pathway activation appears to be a frequent pathogenic feature
of all endometrial carcinoma subtypes, not only of type I
tumours. An important question for future research will be to
characterize what causes the hyperactivation of PI3K-mTORC1
pathway signalling in type II tumours as PTEN mutations are
known to be very rare in this group of tumours (An et al, 2004;
Catasus et al, 2009; Salvesen et al, 2009; Tashiro et al, 1997).
Interestingly, we have previously observed a high rate of loss of
PTEN immunoexpression in type II endometrial carcinomas
(Dellas et al, 2009), suggesting that mechanisms other than
deletion or mutation, for example promoter hypermethylation
or microRNA-mediated silencing, may potentially contribute to
PTEN inactivation in type II cancers. Several studies have also
identified amplifications or activating mutations in the genes
encoding the catalytic and regulatory subunits of PI3K, namely
PIK3CA, PIK3R1 and PIK3R2 in both type I and type II tumours
(Catasus et al, 2009; Cheung et al, 2011; Salvesen et al, 2009;
Urick et al, 2011).
While numerous previous smaller studies investigating the
significance of TP53 mutation status or p53 immunoreactivity
have demonstrated that p53-deficient endometrial carcinomas
tend to have a poor survival outcome, these studies in most
cases failed to demonstrate a prognostic importance of p53 in
multivariate survival analyses (reviewed in Lee et al, 2009). By
analysing the largest patient cohort to date we show that the
immunoexpression level of p53, which has been best described 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.as being involved in the pathogenesis of aggressive type II
tumours, is also a powerful predictor of poor patient survival in
type I tumours. Deep sequencing of exons 5–8 of the TP53 gene
showed a strong correlation between the p53 IHC staining score
and TP53 gene mutation in many tumours. The absence of
highly abundant TP53 mutations in a sub-fraction of tumours
that exhibit a strong p53 IHC score is likely attributable to TP53
mutations in other exons that were not sequenced here or due to
aberrant stabilization of p53 due to alterations in one of the
many regulatory pathways that control p53 protein stability and
function. We demonstrate that TP53 mutations that are
predicted to have a strong detrimental functional impact on
the p53 protein are frequently enriched in the population of
tumour cells in type I or type II endometrial tumours, consistent
with the idea that these mutations provide a proliferative
advantage to the individual tumour cells that harbour these
mutations. In summary, irrespective of endometrial carcinoma
subtype, grade or FIGO stage, we find that strong p53 nuclear
immunoreactivity represents an excellent marker to stratify
patients into poor outcome groups, even in low-grade and low-
FIGO stage tumours. We suggest that these patients, who
would otherwise be stratified into a relatively low-risk group,
should actually be considered as high-risk patients who would
benefit from additional monitoring and therapy, possibly
including the use of drugs to inhibit the PI3K pathway and/or
strategies to kill p53 deficient tumour cells (Lane et al, 2010).We
suggest that further clinical studies should investigate the
possible value of performing p53 immunohistochemistry as a
routine procedure to assist with risk stratification of endometrial
carcinomas.
Given that aggressive type I and type II endometrial
carcinomas exhibit similar patterns of p53 inactivation and
PI3K pathway activation, we argue that the differences between
these two subtypes may in fact be minimal and encourage that
these aggressive tumour types should be viewed as being
‘molecularly similar’ rather than ‘histologically different’. One
of the major differences between the pathogenesis of type I and
type II endometrial cancers may lie in their origin and the order
of occurrence of mutations in TP53 and in the PI3K pathway.
Precursor lesions of type I endometrioid carcinomas, termed
complex atypical hyperplasia, frequently exhibit loss of
expression or mutational inactivation of PTEN, demonstrating
that PI3K pathway activation is a very early event in type I
tumour formation (Hayes et al, 2006; Tantbirojn et al, 2008).
The presence of functional wild-type p53 in these early lesions
likely suppresses aggressive tumour formation. Our clinical data
strongly support the notion that the mutation of TP53 in type I
tumours converts them to an aggressive tumour type, reflected
in the poor survival of patients whose type I tumours exhibited
frequent strong p53 nuclear immunoreactivity. In contrast, type
II tumours arise from precursor lesions that already lack p53
function, making them highly prone to very rapidly form
aggressive tumours in response to ‘second hit’ mutations, such
as those in the PI3K pathway or ERBB2, leading to a very poor
clinical outcome for these patients. Consistent with these ideas,
uterine-specific double knockout of Pten and Trp53 caused
tumours to form more rapidly than in mice harbouring deletionEMBO Mol Med 4, 808–824 www.embomolmed.org
Research Article
Peter J. Wild et al.
The paper explained
PROBLEM:
Endometrial carcinomas of the uterus are the most common
tumour type that develops in the female genital tract. The most
frequent form of these tumours are so-called type I endometrioid
carcinomas which typically have a relatively good prognosis. On
the other hand, the rarer but more aggressive type II endometrial
carcinomas, comprising serous carcinomas, clear cell carcinomas
and undifferentiated carcinomas, account for a disproportionate
number of endometrial cancer-associated deaths. The molecular
causes of these different forms of cancer remain incompletely
understood.
RESULTS:
We find that deletion of the Trp53 tumour suppressor gene in the
endometrium of mice causes the formation of all subtypes of
type II endometrial carcinomas. The accuracy of this mouse
model is reflected by the fact that tumours arise from dysplastic
precursor lesions that are identical to those that are believed to
represent the first steps in the development of human
endometrial cancers. We identify that dysregulation of the
PI3K-mTOR signaling pathway plays an important role in the
development of type II tumours in mice and in humans and that
the status of the p53 tumour suppressor protein is a very
powerful predictor of the aggressiveness of both type I and type II
subtypes of human endometrial tumours.
IMPACT:
This highly accurate mouse model of type II endometrial carcinomas
will facilitate future studies of the causes of these cancers.of Pten alone (Daikoku et al, 2008). Unfortunately, the
histological appearance of these double knockout tumours
was not reported. Moreover, sequencing of PTEN, PIK3CA and
TP53 in human endometrial carcinomas revealed that mutations
in either PTEN or PIK3CA together with concomitant mutation in
TP53 predicted a worse patient outcome than for tumours with
TP53 mutation alone (Catasus et al, 2009).
In summary, our data derived from Trp53 deficient mice and
from human tumour samples form the basis of a new
understanding of tumour formation in the endometrium. We
suggest that PI3K-mTOR pathway activation and TP53 inactiva-
tion play different roles in the initiation of type I and type II
endometrial cancer initiation but that combined signalling
pathway alterations in both PI3K and/or mTORC1 and p53 are a
frequent unifying pathogenic feature of late stage tumours of
both subtypes.MATERIALS AND METHODS
Mouse genetics and analyses
Trp53fl/fl mice (FVB.129-Trp53tm1Brn; Jonkers et al, 2001) from the NCI
Frederick Mouse Repository were crossed to C57BL/6J Ksp1.3-Cre mice
(Shao et al, 2002) obtained from Dr. Peter Igarashi (UT Southwestern,
USA) to generate þ/þ;Trp53fl/fl (WT) and Ksp1.3-Cre/þ;Trp53fl/fl
(Trp53D/D) mice. The Ksp1.3-Cre transgene was genotyped as described
(Shao et al, 2002). Genotyping of the Trp53fl allele and detection of
Cre-mediated recombination at the Trp53 locus were performed as
described (Jonkers et al, 2001). Real-time PCR was performed using
the following primer pairs for Trp53 (50-GCGTAAACGCTTCGAGATGTT-30
and 50-TTTTTATGGCGGGAAGTAGACTG-30) and for 18S rRNA (50-
GTTCCGACCATAAACGATGCC-30 and 50-TGGTGGTGCCCTTCCGTCAAT-30).
Littermate controls were used in all experiments. Mouse experiments
were conducted in accordance with the ethical guidelines of the
Canton of Zurich.www.embomolmed.org EMBO Mol Med 4, 808–824 Antibodies
The following antibodies were used: PI3K p110a (Cell Signaling
Technology, #4255), PTEN (Dako, M3627), phospho-Ser473-AKT (Cell
Signaling Technology, #4051), phospho-Ser9-GSK3b, phospho-
Ser2448-mTOR (Cell Signaling Technology, #2976), phospho-
Thr421/Ser424-p70 S6 Kinase (Cell Signaling Technology, #9204),
phospho-Ser240/244-ribosomal S6 protein (Cell Signaling Technology,
#2215), phospho-Thr37/46-4E-BP1 (Cell Signaling Technology,
#2855), p53 (Dako, M7001), p16 (Santa Cruz Biotechnology, sc-
56330), human ERBB2 (Novacastra Laboratories, NCL-L-CBE-356),
mouse ERBB2 (Abcam, ab2428), phospho-Tyr1248-ERBB2 (Sigma
Aldrich, SAB4300061), phospho-Thr202/Tyr204-ERK1/2 (Cell Signal-
ing Technology, #4376), phospho-Ser217/221-MEK1/2 (Cell Signaling
Technology, #9121), phospho-Thr183/Tyr185-SAPK/JNK (Cell Signaling
Technology, #9251), PAX8 (Protein Tech Group, 10336-1-AP), IMP3
(Dako, M3626), TSC1 (Abcam, ab59273) and TSC2 (Abcam, ab32936).
Tissue microarrays
TMAs containing 339 (Basel TMA) and 182 (Zurich TMA) formalin-
fixed, paraffin-embedded endometrial cancer tissues were constructed
as previously described (Dellas et al, 2009; Kononen et al, 1998;
Lebeau et al, 2008). Median follow-up of the cohort from Basel was
31.5 months (1–184), and 44.5 months (1–124) for the cohort from
Zurich. The study for both cohorts was approved by the scientific
ethics committee from Basel and Zurich (approval no.: KEK-ZH-NR:
2010-0358). The endometrial carcinoma patients were treated in
academic centers and outpatient clinics. Patients with endometrial
cancer who had localized disease were treated by hysterectomy and
bilateral salpingo-oophorectomy (with or without pelvic and para-
aortic lymphadenectomy). Adjuvant intravaginal radiation therapy
was postoperatively given when invasion of the myometrium or
histologic grade 3 tumour was found. All carcinomas were staged
according to the 7th edition of the International Union Against Cancer
(UICC) and American Joint Committee on Cancer (AJCC) TNM system
(Edge et al, 2010). Histopathologic subtype was determined by two2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 821
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822authors (H. M. and R. C.) with the aid of IHC staining in questionable
cases. Histologic grading was according to the FIGO grading system
based on the ratio of glandular or papillary structures versus solid
tumour growth (grade 1, <5% solid tumour; grade 2, 6–50% solid;
and grade 3, >50% solid; Creasman, 2009). Follow-up information
about metastasis, and causes of death were obtained from the
participating departments of gynecology at the University Hospital
Basel, University Hospital Zurich, Cantonal Hospital in Liestal/Base-
l-County and Women’s Hospitals in Loerrach and Rheinfelden, and
from the Cancer Registries of Basel and Zurich. Survival time
was calculated from the time of biopsy diagnosis to the death of
patients.
Immunohistochemistry
Three micrometres of TMA or mouse tissue sections were subjected to
antigen retrieval (microwave oven for 10min at 250W) and
immunohistochemistry was carried out in a NEXES immunostainer
(Ventana, Tucson, AZ, USA). Two surgical pathologists (P. J. W. and K. I.)
performed a blinded evaluation of the immunostained slides without
knowledge of clinical data. For the analysis of p53 staining, tumours
were scored in five groups based on the extent of p53 positivity by
determining the frequency of tumour cells displaying strong nuclear
staining (0, 1–10, 11–50, 51–90 and 91–100%). Focal weak nuclear
p53 staining was regarded as background and scored as 0%. ERBB2
expression was scored according to the DAKO HercepTest criteria.
Cytoplasmic immunoreactivity of p16, IMP3, P-GSK3b, P-S6, P-S6K,
P-4E-BP1, PTEN, P-AKT, P-mTOR and nuclear immunoreactivity of
p110a, PAX8 and P-S6K was estimated using a semi-quantitative
four-step scoring system (0–3): 0, negative; 1, weak positive; 2, strong
positive; 3, very strong positive.
Deep sequencing analysis
DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen) from
punches taken from the same region on the paraffin blocks as used for
TMA construction. Fifty nanograms of DNA was used as input for TP53
PCR amplification (AmpliTaq Gold, Roche) with fusion primers
including multiplex identifiers (MID; see Supporting Information).
Amplicons were checked on a 1% agarose gel for proper amplification.
Amplicon processing was conducted as described by the Amplicon
Library Preparation and emPCR (Lib-A) Method GS Junior Titanium
Series manual from Roche. Shortly, amplicons were purified using
Agencourt AMPure XP beads (Beckman Coulter) and quantified with
the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen). Forty-five
amplicons (9 patients with five amplicons each) were mixed in
equimolar ratio per sequencing run. Emulsion PCR (emPCR) was
performed with 106 molecules and 5,00,000 enriched beads were
loaded on a 454 Junior Sequencer from Roche. Demultiplexing and
variant calling was done with the Amplicon Variant Analyser (AVA)
software from Roche. Variants with zero reads in either forward or
reverse direction were discarded. Additionally, only variants with at
least 50 reads were included in the analysis. Variants were further
analysed using the Mutation Assessor software (http://mutationasses-
sor.org/) and scored as 3, 2 and 1 with high, medium and low-
functional impact, respectively. Deletions, insertions and missense
mutations generating a STOP codon were scored as high-impact
mutations (score 3). Statistical analysis involved a one-way ANOVA
with subsequent Bonferroni’s multiple comparison test. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Statistical analyses
The univariate proportional hazard models used to generate risk
scores are described in detail in Supporting Information. A multi-
variable Cox regression model was learned for testing the independent
prognostic relevance of the risk score and other variables. The
proportionality assumption for all variables was assessed with log-
negative-log survival distribution functions. Non-parametric Kaplan–
Meier estimators were used to analyse overall survival. Differences
between survival estimates were assessed with the log-rank test (LRT).
A statistical association between clinic-pathological and molecular
parameters was tested using a two-sided Fisher’s exact test. In case of
multiple statistical tests the Bonferroni–Holm procedure was applied.Author contributions
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